Author: Courtney Adkins

New Studies Support Exactech’s Shoulder, Knee, Hip and Computer-Assisted Surgery Technologies

Exactech Innovations Presented at International Scientific Conference

GAINESVILLE, Fla. (Oct. 18, 2018) – Exactech, a developer and producer of innovative implants, instrumentation and computer-assisted technologies for joint replacement surgery, announced today that 14 studies involving its knee, hip and shoulder joint replacement innovations and its ExactechGPS® guided personalized surgery system were recently featured at the 31st Congress of The International Society for Technology in Arthroplasty (ISTA) in London, United Kingdom.

Studies featuring Exactech technologies included:

Shoulder Arthroplasty 

Effect of Screw Length and Screw Number on Reverse Shoulder Glenoid Fixation
Christopher Roche; Jose Yegres; Nick Stroud; Jennifer VanDeven; Thomas Wright; Pierre Henri Flurin; Joseph Zuckerman

Inter-Surgeon Variability in Using 3D Planning Software for Anatomic Total Shoulder Arthroplasty: an Analysis of 360 Cases
Alexander Greene; Emilie Cheung; Sandrine Polakovic; Matthew Hamilton; Richard Jones; Ari Youderian; Thomas Wright; Paul Saadi; Joseph Zuckerman; Pierre Henri Flurin; Ira Parsons

Navigated vs. Non-Navigated Results of a CT Based Computer Assisted Shoulder Arthroplasty System in 30 Cadavers
Alexander Greene; Matthew Hamilton; Sandrine Polakovic; Nicole Mohajer; Ari Youderian; Thomas Wright; Ira Parsons; Paul Saadi; Emilie Cheung; Richard Jones

Inter-Surgeon Variability in Using 3D Planning Software for Reverse Total Shoulder Arthroplasty: an Analysis of 360 Cases
Alexander Greene; Emilie Cheung; Sandrine Polakovic; Matthew Hamilton; Richard Jones; Ari Youderian; Thomas Wright; Paul Saadi; Joseph Zuckerman; Pierre Henri Flurin; Ira Parsons

A New Quantitative Load Balancing Sensor for Reverse Total Shoulder Arthroplasty
Matthias Verstraete; Michael Conditt; Thomas Wright; Joseph Zuckerman; Ari Youderian; Ira Parsons; Richard Jones; Joseph Decerce; Gordon Goodchild; Alexander Greene; Christopher Roche


 

Knee Arthroplasty

Comprehensive Femoral Component Fit Assessment on Mediolateral Overhang and Sulcus Restoration
Yifei Dai; Georgios Papantonakis; Sjoerd Kolk; Danielle Beski; Laurent Angibaud

Coronal Laxity in Total Knee Arthroplasty: an Intraoperative Measurement
Yifei Dai; Amaury Jung; Guillaume Bras; David Liu

Improved Accuracy in Total Knee Arthroplasty by CAOS Enhanced Mechanical Instrumentation
Yifei Dai; James Huddleston; Matthew Rueff; Laurent Angibaud; Derek Amanatullah

Learning of a CAOS Enhanced Mechanical Instrument System for Total Knee Arthroplasty: A CUSUM Analysis
Yifei Dai; James Huddleston; Matthew Rueff; Laurent Angibaud; Derek Amanatullah

Learning Computer-Assisted Total Knee Arthroplasty: A CUSUM Analysis on Ten Surgeons
Yifei Dai; Guillaume Bras; Cyril Hamad

Compromise in Component Placement: A Comparison Between Symmetric and Anatomic Patellar Designs
Yifei Dai; Pierre Angibaud; H Morton Bertram


Hip Arthroplasty

Hip Wear Simulator Results of Vitamin E Blended Highly Crosslinked Polyethylene
Hilary Feskanin; Brady Barnes; Edmund Loftus; Nick Stroud

Early Clinical Outcomes of a Tapered Wedge Femoral Hip Stem
Matthew Peterson; Hilary Feskanin; Jeffery Pierson

Implant Fixation and Early Clinical Outcomes of a 3D-Printed Acetabular Cup
Matthew Peterson; Hilary Feskanin; Yassaman Najmabadi; Raymond Robinson

About ISTA

The International Society for Technology in Arthroplasty (ISTA) is a nonprofit corporation whose goal is to promote public awareness, education and research, in arthroplasty. The means by which this purpose is achieved is through ISTA’s Annual Congress where emerging technologies are discussed between surgeons, engineers, and industry.

About Exactech

Based in Gainesville, Fla., Exactech develops and markets orthopaedic implant devices, related surgical instruments and biologic materials, as well as computer assistance and other Augmented OrthopaedicTM technologies to hospitals and physicians. The company manufactures many of its orthopaedic devices at its Gainesville facility. Exactech’s orthopaedic products are used in the restoration of bones and joints that have deteriorated as a result of injury or diseases such as arthritis. Exactech markets its products throughout the United States and in more than 30 markets in Europe, Latin America, Asia and the Pacific. Additional information about Exactech can be found at staging.exac.com.

Exactech Welcomes Orthopaedic Sales Veteran Stuart Kleopfer as Senior VP of Global Sales

GAINESVILLE, Fla. (Oct. 2, 2018) – Exactech, a developer and producer of innovative implants, instrumentation and computer-assisted technologies for joint replacement surgery announced today the appointment of Stuart Kleopfer as Senior Vice President of Global Sales, effective Oct. 1, 2018.

Kleopfer will provide leadership for Exactech’s global sales functions with responsibility for the United States sales organization and the company’s current international team. Kleopfer is a veteran of the orthopaedics industry with 30 years experience in sales and marketing. He had a distinguished career at Biomet that included serving as president, U.S. Commercialization, and then with ZimmerBiomet where he served as president, Americas, until 2017.

“I am excited to be back in orthopaedics and look forward to re-engaging with surgeons and sales representatives…”

Stuart Kleopfer

“I am excited to be back in orthopaedics and look forward to re-engaging with surgeons and sales representatives,” Kleopfer said. “Exactech has a great product offering and with what we have in the research and development pipeline, I am confident we will be able to strengthen our global sales channel, generate top line revenue and grow market share.”

According to Exactech CEO David Petty, “Stuart is a great addition to Exactech and an excellent fit for our surgeon-focused culture. It’s an exciting time of growth for the company and we are eager to leverage Stuart’s expertise,” he said.

Exactech Co-Executive Chairman Jeff Binder also commented, “We are excited to add Stuart, with his proven track record of success, to the Exactech team and I am looking forward to working with him again.”

 


 

About Exactech

Based in Gainesville, Fla., Exactech develops and markets orthopaedic implant devices, related surgical instruments, and biologic materials, as well as computer assistance and other Augmented OrthopaedicTM technologies to hospitals and physicians. The company manufactures many of its orthopaedic devices at its Gainesville facility. Exactech’s orthopaedic products are used in the restoration of bones and joints that have deteriorated as a result of injury or diseases such as arthritis. Exactech markets its products throughout the United States and in more than 30 markets in Europe, Latin America, Asia and the Pacific. Additional information about Exactech can be found at staging.exac.com.

Exactech Earns Research Award at International Computer-Assisted Surgery Conference for ExactechGPS® Knee Application

Gainesville, Fla. (June 20, 2018) – Exactech, a leading developer and producer of bone and joint restoration products and biologic solutions for extremities, knee and hip, earned the Second Place Best Clinical Podium Presentation Award for one of five new research studies presented on the company’s latest computer guidance technology for knee surgery at the International Society for Computer Assisted Orthopaedic Surgery (CAOS) annual meeting in Beijing, China earlier this month.

The award-winning research demonstrated the potential for ExactechGPS to accurately manage soft tissue balance, bone cuts and overall alignment of the knee in joint replacement surgery.

According to Orthopaedic Surgeon David Liu, MD, of The Gold Coast Centre for Bone & Joint Surgery in Queensland, Australia, “It was an honour to present several studies based on ExactechGPS and to receive this award, along with my co-authors Yifei Dai and Guillaume Bras of Exactech. This scientific meeting is unique in its focus on the role of navigation in orthopaedic surgery. I am confident that this technology plays a major role in the outcomes of joint arthroplasty.”

The five ExactechGPS studies presented at CAOS 2018 add to the more than 20 presented so far this year, including one that was recognized as the 2018 Orthopaedic Research Society’s Best Implant Poster Award. For more information on Exactech’s solutions for knee replacement and its ExactechGPS technology, visit staging.exac.com.

About Exactech

Based in Gainesville, Fla., Exactech develops and markets orthopaedic implant devices, related surgical instruments and biologic materials and services to hospitals and physicians. The company manufactures many of its orthopaedic devices at its Gainesville facility. Exactech’s orthopaedic products are used in the restoration of bones and joints that have deteriorated as a result of injury or diseases such as arthritis. Exactech markets its products in the United States, in addition to more than 30 markets in Europe, Latin America, Asia and the Pacific. Additional information about Exactech can be found at https://staging.exac.com.

Exactech Provides Powerful Combination of Computer Technology and Award-Winning Instrumentation for Revision Knee Surgery

First Surgery Performed using new ExactechGPS® RTKA Application and Truliant® Knee System Instrumentation

GAINESVILLE, Fla. (May 22, 2018) – Exactech, a developer and producer of bone and joint restoration products and biologic solutions for extremities, knee and hip, announced today that two of its leading technologies were used in combination for the first time to support a revision total knee surgery. Bernard Stulberg, MD, at the St. Vincent Charity Medical Center in Cleveland, Ohio, performed the first case using the new ExactechGPS® revision knee software application (RTKA), along with the company’s award-winning Truliant® Knee System instrumentation.

ExactechGPS is a surgeon-controlled, computer-assisted surgical technology that provides real-time, intraoperative data during total joint arthroplasty. The RTKA application helps orthopaedic surgeons address complex primary and challenging revision cases by providing insights into the diseased joint, feedback of anatomical and mechanical alignment, component sizing and resection validation.

According to Dr. Stulberg, a revision knee specialist, “I had the opportunity to experience firsthand the powerful potential of the Truliant instrumentation combined with ExactechGPS. The RTKA application revealed the existing abnormalities that caused my patient’s disability, and helped guide the sizing and positioning of the implants. The result was restoration of alignment and stability of a previously unstable total knee arthroplasty.”

ExactechGPS has a proven ability to achieve high accuracy and precision in resection alignment1 and is the only computer-assisted surgical technology to offer surgeons advanced ligament balancing options for RTKA. Fully integrated with the ExactechGPS technology, Exactech provides a comprehensive array of revision implant options, including metaphyseal cones, stems, augments and offset couplers.

“Exactech’s revision system leaves no doubt it can simplify procedures, while providing the framework to consistently deliver successful results for the wide range of complications in RTKA,” Stulberg said. “I am fully confident this will result in significant and meaningful benefits for both the surgeon and the patient.”

The Truliant revision instrumentation has full U.S. market availability. The ExactechGPS RTKA application is currently in pilot launch with full availability expected in the second half of the year. For more information, visit www.TruliantKnee.com.

  1. Dai Y et al. Total Knee Arthroplasty Using a Contemporary Computer Assisted Surgical System: A Review of Resection Alignment on 8,000 Clinical Cases. ORS Best Implant Poster Award.

About Exactech

Based in Gainesville, Fla., Exactech develops and markets orthopaedic implant devices, related surgical instruments and biologic materials and services to hospitals and physicians. The company manufactures many of its orthopaedic devices at its Gainesville facility. Exactech’s orthopaedic products are used in the restoration of bones and joints that have deteriorated as a result of injury or diseases such as arthritis. Exactech markets its products in the United States, in addition to more than 30 markets in Europe, Latin America, Asia and the Pacific. Additional information about Exactech can be found at https://staging.exac.com.

Exactech Knee Research Honored with Orthopaedic Research Society’s Best Implant Poster Award

Gainesville, Fla. (April 3, 2018) – Exactech, a leading developer and producer of bone and joint restoration products and biologic solutions for extremities, knee and hip, announced today that its research, “Total Knee Arthroplasty Using a Contemporary Computer-Assisted Surgical System: A Review of Resection Alignment on 8,000 Clinical Cases,” received the Orthopedic Implant Section Best Poster Award at the 2018 Orthopaedic Research Society (ORS) Annual Meeting in New Orleans, La.

The study was based on a large collection of technical reports on all the total knee arthroplasty cases performed in the entire application history of ExactechGPS®, Exactech’s surgeon-controlled computer-assisted surgery for improved reproducibility and efficiency in total joint arthroplasty. The results demonstrated high accuracy and precision in resection alignment with the use of the system by users with varying levels of experience.

Two additional posters, featuring the Truliant® Knee System’s femoral and patellar designs, were recognized as poster finalists in the same category. According to Co-Author H. Morton Bertram III, MD, “Truliant’s new design has had a very positive impact. I find that I can improve coverage of the native bone with the more anatomic patella.”

“The recognition from ORS is an incredible achievement that shows our commitment to research and surgeon input to deliver a clinically engineered system that addresses surgeons’ needs for reproducibility in total knee arthroplasty,” said Vice President of Knee Marketing Joseph Pizzurro. “We are pleased to receive such a positive response to Truliant’s comprehensive platform, including its state-of-the-art ExactechGPS knee applications and anatomical implant design.”

In the shoulder and orthopedic implant categories, the Equinoxe® Shoulder System was also recognized as a finalist for two different posters. The research featured a comprehensive outcome study of nearly 1,600 patients, the analysis of which provided surgeons a new threshold to quantify outcomes after total shoulder arthroplasty; this work was also recently published in the Journal of Shoulder and Elbow Surgery.

Exactech was well represented at the meeting with a total of 23 scientific posters and presentations featuring its latest innovations for shoulder, knee, hip and biologics.

About Exactech

Based in Gainesville, Fla., Exactech develops and markets orthopaedic implant devices, related surgical instruments and biologic materials and services to hospitals and physicians. The company manufactures many of its orthopaedic devices at its Gainesville facility. Exactech’s orthopaedic products are used in the restoration of bones and joints that have deteriorated as a result of injury or diseases such as arthritis. Exactech markets its products in the United States, in addition to more than 30 markets in Europe, Latin America, Asia and the Pacific. Additional information about Exactech can be found at https://staging.exac.com.

Media Contact

Priscilla Bennett
Vice President, Corporate & Marketing Communication
(352) 377-1140
media@exac.com

Exactech’s Vitamin E Acetabular Polyethylene Liner for Hip Replacement Gains FDA 510(k) Clearance

Gainesville, Fla. (March 19, 2018) – Exactech, a developer and producer of bone and joint restoration products and biologic solutions for extremities, knee and hip announced today it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market the Novation XLE Vitamin E acetabular polyethylene liners for hip replacement surgery. These liners are designed to work in conjunction with the Novation® Crown Cup® Acetabular System including InteGrip® printed, 3-D porous material.

The advanced bearing material in the new XLE liners is designed for low wear and contains vitamin E. Oxidation in-vivo can contribute to polyethylene degradation in orthopaedic implant polyethylene. Vitamin E, a natural antioxidant, is blended into the raw material of Novation XLE liners to mitigate oxidative effects both before and after implantation.

This product complements Exactech’s Hip product family, which also includes the Alteon® HA Femoral Stem, Tapered Wedge Femoral Stem, Neck Preserving Stem and Monobloc Revision Stem.

About Exactech

Based in Gainesville, Fla., Exactech develops and markets orthopaedic implant devices, related surgical instruments and biologic materials and services to hospitals and physicians. The company manufactures many of its orthopaedic devices at its Gainesville facility. Exactech’s orthopaedic products are used in the restoration of bones and joints that have deteriorated as a result of injury or diseases such as arthritis. Exactech markets its products in the United States, in addition to more than 30 markets in Europe, Latin America, Asia and the Pacific. Additional information about Exactech can be found at https://staging.exac.com.

Media Contact

Priscilla Bennett
Vice President, Corporate & Marketing Communication
(352) 377-1140
media@exac.com

Exactech Knee System, Ankle, Shoulder Stem, Hip Stem and Computer-Assisted Surgery Technology Headline at Booth #5023, AAOS 2018 Annual Meeting

GAINESVILLE, Fla. (March 6, 2018) – Exactech, a developer and producer of bone and joint restoration products and biologic solutions for extremities, knee and hip announced today its lineup of products to be showcased at the company’s educational exhibit at Booth #5023 at the American Academy of Orthopaedic Surgeons (AAOS) 2018 Annual Meeting, March 7-9, in New Orleans, La.

The Exactech innovations and educational opportunities to be showcased at Booth #5023 are featured on the company website and include:

The new Truliant® Knee System, a surgeon inspired primary and revision knee system designed for an efficient and reproducible experience, featuring Exactech’s new award-winning instrumentation. Seamlessly integrating with the ExactechGPS® guided personalized surgery system, Truliant supports a simple transition to computer-assisted surgery for real-time data and guidance with only two block changes using the new ExactechGPS TKA Plus Application.

The Equinoxe® Preserve is the next generation platform shoulder stem. Designed to preserve distal humeral bone while also achieving optimal stability and fixation, this platform stem is compatible with the Equinoxe® Shoulder System that uniquely focuses on anatomical replication, reverse shoulder arthroplasty and options for difficult glenoids and revisions. It can be used with the ExactechGPS Shoulder Application, the only computer-assisted surgical technology for shoulder arthroplasty. It supports surgeons from pre-operative planning through real-time execution.

The Alteon® HA Femoral Hip Stem with hydroxyapatite-coating is designed to be bone conserving, while providing initial stability to promote biologic fixation. It features reduced stem lengths, incremental stem sizing, and proportional neck geometry with a broach-only technique that offers flexibility to accommodate various surgical approaches.

The Vantage® Total Ankle System represents a new perspective in ankle arthroplasty and is Exactech’s first product in the foot and ankle market. The Vantage ankle focuses on antaomic design, fixation, biomechanics, bone removal, reliability and revision.

The InterSpace® Tapered Wedge hip spacer provides surgeons the same consistent local antimicrobial activity as the cylindrical spacer, in a new wedge-style stem design to treat patients following peri-prosthetic joint infection.

Reveille® Cartilage Processor, a cost-effective option for single stage surgery with autologous cartilage, is used for intraoperative resizing of autologous tissue into usable particles.

Scientists and surgeon consultants are scheduled at the Exactech booth to share their experiences with the company’s products. Attendees may also learn about Exactech’s patient education and practice marketing programs.

About Exactech

Based in Gainesville, Fla., Exactech develops and markets orthopaedic implant devices, related surgical instruments and biologic materials and services to hospitals and physicians. The company manufactures many of its orthopaedic devices at its Gainesville facility. Exactech’s orthopaedic products are used in the restoration of bones and joints that have deteriorated as a result of injury or diseases such as arthritis. Exactech markets its products in the United States, in addition to more than 30 markets in Europe, Latin America, Asia and the Pacific. Additional information about Exactech can be found at https://staging.exac.com.

Media Contact

Priscilla Bennett, APR
Exactech Vice President, Corporate & Marketing Communication
(352) 377-1140
media@exac.com

Orthopaedic Industry Veteran Jeffrey R. Binder Joins Bill Petty, MD, as Co-Executive Chairman of Exactech; Daniel Hann Joins Exactech as Sr. Vice President of Business Development

GAINESVILLE, Fla. (March 5, 2018) – Exactech, a developer and producer of bone and joint restoration products and biologic solutions for extremities, knee and hip announced today the appointment of Jeffrey R. Binder who joins Bill Petty, MD as Co-Executive Chairman following the company’s recent go-private merger agreement with TPG Capital.

Binder, 25-year veteran of the medical device and diagnostics industry, has proven expertise in helping companies realize growth opportunities. He has served in CEO roles for Biomet and Immucor, and previously held senior roles at Abbott and Johnson & Johnson.

Daniel Hann, who held leadership positions with Biomet for more than 25 years, has also joined Exactech as Senior Vice President of Business Development.

“I am excited to join a company that I have admired for many years.” Binder said. “Exactech has made its mark through its excellent products and also as a company that lives its values. I look forward to working with Dr. Petty, CEO David Petty and the rest of Exactech’s passionate team as we grow to reach even more surgeons and patients around the globe.”

Exactech CEO David Petty said “We are excited to have Jeff and Dan joining the Exactech team. Their years of relevant experience and compatibility with our culture will make them valuable leaders and contributors to our future success.”

About Exactech

Based in Gainesville, Fla., Exactech develops and markets orthopaedic implant devices, related surgical instruments and biologic materials and services to hospitals and physicians. The company manufactures many of its orthopaedic devices at its Gainesville facility. Exactech’s orthopaedic products are used in the restoration of bones and joints that have deteriorated as a result of injury or diseases such as arthritis. Exactech markets its products in the United States, in addition to more than 30 markets in Europe, Latin America, Asia and the Pacific. Additional information about Exactech can be found at https://staging.exac.com.

Media Contact

Priscilla Bennett, APR
Exactech Vice President, Corporate & Marketing Communication
(352) 377-1140
media@exac.com

Exactech Announces Completion of Merger with TPG Capital

Gainesville, Fla. (Feb. 14, 2018) – Exactech (Nasdaq: EXAC), a leading developer and producer of orthopaedic implant devices and surgical instrumentation for extremities and large joints, is pleased to announce the successful completion of the previously announced merger agreement with TPG Capital, pursuant to which TPG has acquired all of the issued and outstanding common stock of Exactech. In connection with the transaction, Exactech shareholders will receive $49.25 in cash for each share of Exactech common stock they hold (other than certain shares held by the Company’s founders and certain management shareholders). Pursuant to the previously announced rollover and voting support agreement, the Company’s founders, CEO and certain other management shareholders have exchanged a portion of their shares in the transaction, representing approximately 18.8% of the Company’s outstanding common stock, for new equity securities in the post-closing ownership of the Company at a valuation equal to or less than $49.25 per share. The total transaction is valued at approximately $737 million.

As a result of the transaction, Exactech’s common stock will cease trading on the Nasdaq immediately prior to market open on February 15, 2018, and will no longer be listed on the Nasdaq. Exactech intends to file the relevant form with the Securities and Exchange Commission (the “SEC”) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), requesting the deregistration of its common stock and the suspension of Exactech’s reporting obligations under the Exchange Act.

The closing of the transaction follows the approval of Exactech’s shareholders at a special meeting held yesterday and the satisfaction of all closing conditions.

Advisors

Greenberg Traurig, P.A. (Miami) and Greenberg Traurig, LLP (NYC) are acting as Exactech’s legal advisor. J.P. Morgan Securities LLC is acting as financial advisor to Exactech. Ropes & Gray LLP is acting as legal advisor to TPG Capital.

About Exactech

Based in Gainesville, Fla., Exactech develops and markets orthopaedic implant devices, related surgical instruments and biologic materials and services to hospitals and physicians. The company manufactures many of its orthopaedic devices at its Gainesville facility. Exactech’s orthopaedic products are used in the restoration of bones and joints that have deteriorated as a result of injury or diseases such as arthritis. Exactech markets its products in the United States, in addition to more than 30 markets in Europe, Latin America, Asia and the Pacific. Additional information about Exactech can be found at https://staging.exac.com.

About TPG

TPG is a leading global alternative asset firm founded in 1992 with more than $73 billion of assets under management and offices in Austin, Beijing, Boston, Dallas, Fort Worth, Hong Kong, Houston, London, Luxembourg, Melbourne, Moscow, Mumbai, New York, San Francisco, Seoul, and Singapore. TPG’s investment platforms are across a wide range of asset classes, including private equity, growth venture, real estate, credit, and public equity. TPG aims to build dynamic products and options for its investors while also instituting discipline and operational excellence across the investment strategy and performance of its portfolio. For more information, visit www.tpg.com.

Media Contacts

Luke Barrett, TPG
media@tpg.com
415-743-1550

Priscilla Bennett, Exactech
media@exac.com
352-377-1140

Forward-Looking Statements

This press release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Exchange Act. These forward-looking statements include, but are not limited to, statements regarding Exactech’s business combination transaction with TPG Capital, all statements regarding Exactech’s expected future financial position, results of operations, cash flows, dividends, financing plans, business strategy, budgets, capital expenditures, competitive positions, growth opportunities, plans and objectives of management, and statements containing the words such as “anticipate,” “approximate,” “believe,” “plan,” “estimate,” “expect,” “project,” “could,” “would,” “should,” “will,” “intend,” “may,” “potential,” “upside,” and other similar expressions. All Statements in this press release that are not historical facts, are forward-looking statements that reflect the best judgment of Exactech based upon currently available information.

Such forward-looking statements are inherently uncertain, and shareholders and other potential investors must recognize that actual results may differ materially from Exactech’s expectations as a result of a variety of factors, including, without limitation, those discussed below. Such forward-looking statements are based upon management’s current expectations and include known and unknown risks, uncertainties and other factors, many of which Exactech is unable to predict or control, that may cause its actual results, performance or plans to differ materially from any future results, performance or plans expressed or implied by such forward-looking statements. These statements involve risks, uncertainties and other factors discussed below and detailed from time to time in Exactech’s filings with the SEC.

Exactech cautions investors that any forward-looking statements made by it are not guarantees of future performance. Exactech disclaims any obligation to update any such factors or to announce publicly the results of any revisions to any of the forward-looking statements to reflect future events or developments.

Exactech Shareholders Approve Merger Agreement with TPG Capital

Gainesville, Fla. (Feb. 13, 2018) – Exactech (Nasdaq: EXAC), a leading developer and producer of orthopaedic implant devices and surgical instrumentation for extremities and large joints, today announced that at a Special Meeting of Shareholders held earlier today, Exactech’s shareholders approved the previously announced merger agreement with TPG Capital and certain of its affiliates, and approved the other two proposals described in Exactech’s proxy statement relating to today’s meeting.

Approximately 94.5% of voting Exactech shareholders cast their votes in favor of the merger, representing approximately 73.7% of Exactech’s outstanding common stock as of the record date for the special shareholder meeting. The final results will be available on a Current Report on Form 8-K, to be filed later this week by the company.

Upon completion of the transaction, Exactech shareholders will receive an amount in cash equal to $49.25 per share of Exactech common stock. The transaction remains subject to customary closing conditions and is expected to close on or around February 14, 2018, at which time Exactech will become a private company and its common stock will no longer trade on the NASDAQ. In addition, the company’s common stock will cease to be registered under Section 12 of the Securities Exchange Act of 1934, as amended.

Advisors

Greenberg Traurig, P.A. (Miami) and Greenberg Traurig, LLP (NYC) are acting as Exactech’s legal advisor. J.P. Morgan Securities LLC is acting as financial advisor to Exactech. Ropes & Gray LLP is acting as legal advisor to TPG Capital.

About Exactech

Based in Gainesville, Fla., Exactech develops and markets orthopaedic implant devices, related surgical instruments and biologic materials and services to hospitals and physicians. The company manufactures many of its orthopaedic devices at its Gainesville facility. Exactech’s orthopaedic products are used in the restoration of bones and joints that have deteriorated as a result of injury or diseases such as arthritis. Exactech markets its products in the United States, in addition to more than 30 markets in Europe, Latin America, Asia and the Pacific. Additional information about Exactech can be found at https://staging.exac.com.

About TPG

TPG is a leading global alternative asset firm founded in 1992 with more than $73 billion of assets under management and offices in Austin, Beijing, Boston, Dallas, Fort Worth, Hong Kong, Houston, London, Luxembourg, Melbourne, Moscow, Mumbai, New York, San Francisco, Seoul, and Singapore. TPG’s investment platforms are across a wide range of asset classes, including private equity, growth venture, real estate, credit, and public equity. TPG aims to build dynamic products and options for its investors while also instituting discipline and operational excellence across the investment strategy and performance of its portfolio. For more information, visit www.tpg.com.

Media Contacts

Luke Barrett, TPG
media@tpg.com
415-743-1550

Priscilla Bennett, Exactech
media@exac.com
352-377-1140

Forward-Looking Statements

This press release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements include, but are not limited to, statements regarding Exactech’s proposed business combination transaction with TPG Capital, all statements regarding Exactech’s expected future financial position, results of operations, cash flows, dividends, financing plans, business strategy, budgets, capital expenditures, competitive positions, growth opportunities, plans and objectives of management, and statements containing the words such as “anticipate,” “approximate,” “believe,” “plan,” “estimate,” “expect,” “project,” “could,” “would,” “should,” “will,” “intend,” “may,” “potential,” “upside,” and other similar expressions. All Statements in this press release that are not historical facts, are forward-looking statements that reflect the best judgment of Exactech based upon currently available information.

Such forward-looking statements are inherently uncertain, and shareholders and other potential investors must recognize that actual results may differ materially from Exactech’s expectations as a result of a variety of factors, including, without limitation, those discussed below. Such forward-looking statements are based upon management’s current expectations and include known and unknown risks, uncertainties and other factors, many of which Exactech is unable to predict or control, that may cause its actual results, performance or plans to differ materially from any future results, performance or plans expressed or implied by such forward-looking statements. These statements involve risks, uncertainties and other factors discussed below and detailed from time to time in Exactech’s filings with the Securities and Exchange Commission (the “SEC”).

Risks and uncertainties related to the proposed merger include, but are not limited to, the potential adverse reactions or changes to business relationships resulting from the announcement or completion of the merger, uncertainties as to the timing of the merger, adverse effects on Exactech’s stock price resulting from the announcement of the merger or the failure of the merger to be completed, competitive responses to the announcement of the merger, the risk that regulatory, licensure or other approvals required for the consummation of the merger are not obtained or are obtained subject to terms and conditions that are not anticipated, litigation relating to the merger, the inability to retain key personnel, and any changes in general economic and/or industry-specific conditions.

In addition to the factors set forth above, other factors that may affect Exactech’s plans, results or stock price are set forth in its most recent Annual Report on Form 10-K and in its subsequently filed reports on Forms 10-Q and 8-K.

Many of these factors are beyond Exactech’s control. Exactech cautions investors that any forward-looking statements made by it are not guarantees of future performance. Exactech disclaims any obligation to update any such factors or to announce publicly the results of any revisions to any of the forward-looking statements to reflect future events or developments.